Biotech olandese spin-off di Leiden che sviluppa inibitori NNMT per obesita e sindrome metabolica.
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Funding round Cantoni Therapeutics closed a financing round (undisclosed amount) led by Libertatis Ergo Holding with BOM and BSF, plus a Novo Nordisk grant, to bring its NNMT inhibitor to IND stage. | — |